debt_leverage_profile
Near-zero debt; cash-funded clinical-stage biotech with ~€150M+ cash runway; 20% rate rise has negligible P&L impact
Inferred
Agent_Inference
interest_rate_sensitivity
Minimal; no floating-rate debt; higher rates reduce treasury yield on cash reserves by ~€1-3M annually at current balances
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) Netherlands/EU peptide API synthesis capacity; 2) Single-source bradykinin receptor reagent suppliers concentrated in US/EU
Inferred
Agent_Inference
international_expansion_readiness
Pre-revenue; no international revenue markets yet; currency exposure limited to EUR/USD operating cost mismatch
Inferred
Agent_Inference
geographic_footprint
Incorporated Netherlands, operations US/EU; no revenue-generating markets; EUR functional currency with USD burn exposure
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency on single CROs (e.g., Covance/Labcorp) for Phase 3 trials; substitution would delay program 12-18 months
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage biopharma; no cloud-critical revenue operations; AWS/GCP termination would disrupt data systems but not core value
Inferred
Agent_Inference
business_model_type_secondary
R&D-stage drug developer; secondary reliance on cloud for clinical data management; 30-day notice survivable with migration
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; primary technology is proprietary oral bradykinin-B2 antagonist (deucrictibant); not software-API dependent
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is future drug royalties/sales, not investment contracts; equity is standard registered security
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate GDPR exposure from EU clinical trial patient data; CCPA limited; compliance infrastructure typical for EU-domiciled pharma
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche HAE orphan disease market; no dominant market position yet; no horizontal merger concerns currently
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
0% recurring revenue currently; pre-commercial; 100% future revenue will be transactional drug sales or milestone/royalty-based
Inferred
Agent_Inference
monetization_vector
Future monetization via direct drug sales (deucrictibant) and potential licensing milestones; no current commercial revenue
Inferred
Agent_Inference
pricing_architecture
Orphan drug pricing model; HAE on-demand treatment; comparable branded therapies (FIRAZYR, KALBITOR) priced $5,000-$15,000/dose
Inferred
Agent_Inference
pricing_power_rating
High potential pricing power; orphan designation, small patient population, clinical differentiation (oral route) support premium pricing
Inferred
Agent_Inference
target_gross_margin_bracket
Target gross margin 80-90%+ post-commercialization; typical small-molecule oral drug COGS structure supports biotech-standard margins
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider risk; prescription drug model with payer/patient barriers; HAE patients have high treatment adherence by disease severity
Inferred
Agent_Inference
headcount_cost_structure
Headcount-sublinear post-approval; current ~50-person team scales modestly; commercialization adds sales force but not proportionally
Inferred
Agent_Inference
marginal_cost_of_growth
Post-approval revenue growth largely sublinear to headcount; manufacturing outsourced; marginal cost driven by COGS not personnel
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise network; direct biopharma model
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC remains physician/KOL-driven; HAE specialist universe ~500 US physicians limits but concentrates acquisition efficiency
Inferred
Agent_Inference
network_effect_present
No network effects; drug efficacy is independent of user base; value driven by clinical outcomes not adoption scale
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk low for core drug asset; AI could accelerate preclinical pipeline but cannot replace Phase 3 clinical validation
Inferred
Agent_Inference
recession_resistance_tier
High recession resistance; HAE is life-threatening genetic condition requiring treatment regardless of economic cycle; payer-covered
Inferred
Agent_Inference
customer_segment_primary
HAE patients (hereditary angioedema); ~1 in 50,000 prevalence; ~6,000-10,000 diagnosed patients in US, similar in EU
Inferred
Agent_Inference
customer_segment_secondary
Rare disease specialist physicians (allergists, immunologists) and hospital formulary decision-makers as key prescriber segment
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated almost entirely to clinical development (Phase 3 CHAPTER-2/3 trials); no legacy infrastructure reallocation needed
Inferred
Agent_Inference
sec_cik
0001830487
High
SEC-EDGAR
ticker
PHVS
High
SEC-EDGAR